Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD

References

• Johnson S. A successful collaboration between clinical nurse leaders and clinical nurse specialists combating hospital-acquired; 2018. http://journals.lww.com/nursingmanagement
   Google Scholar
• Bao H, Lighter J, Dubrovskaya Y, Merchan C, Siegfried J, Papadopoulos J, Jen S-P. Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection. Pediatrics. 2021;148(2). doi:10.1542/peds.2020-031807.
   PubMed Web of Science ®Google Scholar
• Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016;93(3):286–16. doi:10.1016/j.jhin.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Centre for disease control and prevention. Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services, Centres for Disease Control and Prevention: US Department of Health and Human Services, Centres for Disease Control and Prevention; 2019.
   Google Scholar
• Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884–2892. doi:10.1128/JCM.00845-13.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue Y-K. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431. doi:10.1056/NEJMoa0910812.
   PubMed Web of Science ®Google Scholar
• Rea MC, Sit CS, Clayton E, O’Connor PM, Whittal RM, Zheng J, Vederas JC, Ross RP, Hill C. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci. 2010;107(20):9352–9357. doi:10.1073/pnas.0913554107.
   PubMed Web of Science ®Google Scholar
• Al-Zahrani IA. Clostridioides (Clostridium) difficile: a silent nosocomial pathogen. Saudi Med J. 2023;44(9):825. doi:10.15537/smj.2023.44.9.20230216.
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Cont Hosp Ep. 1995;16(8):459–477. doi:10.2307/30141083.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55(suppl_2):S65–S70. doi:10.1093/cid/cis319.
   PubMedGoogle Scholar
• Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology. 2006;130(4):1311–1316. doi:10.1053/j.gastro.2006.02.044.
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40(11):1586–1590. doi:10.1086/430311.
   PubMed Web of Science ®Google Scholar
• Walter J, Maldonado-Gómez MX, Martínez I. To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes. Curr Opin Biotechnol. 2018;49:129–139. doi:10.1016/j.copbio.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Erikstrup LT, Aarup M, Hagemann-Madsen R, Dagnaes-Hansen F, Kristensen B, Olsen KEP, Fuursted K. Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination. BMJ Open Gastroenterol. 2015;2(1):e000038. doi:10.1136/bmjgast-2015-000038.
   PubMedGoogle Scholar
• Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Cont Hosp Ep. 2010;31(5):431–455. doi:10.1086/651706.
   PubMed Web of Science ®Google Scholar
• Johnson S. 2016. Editorial commentary: potential risks and rewards with prophylaxis for Clostridium difficile infection. Clinical Infectious Diseases: Oxford University Press; p. 654–655.
   Google Scholar
• Crawford T, Huesgen E, Danziger L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012;69(11):933–943. doi:10.2146/ajhp110371.
   PubMed Web of Science ®Google Scholar
• Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis. 2014;5(2):69–84. doi:10.1177/2040622313511285.
   PubMedGoogle Scholar
• Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis. 2012;55(suppl_2):S143–S148. doi:10.1093/cid/cis339.
   PubMedGoogle Scholar
• Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice. Antimicrob Agents Chemother. 2018;62(5):e02112–17. doi:10.1128/AAC.02112-17.
   PubMed Web of Science ®Google Scholar
• Hurst A. 1981. Nisin. Advances in applied microbiology. Vol. 27, p. 85–123. Elsevier.
   Google Scholar
• Jančič U, Gorgieva S. Bromelain and nisin: the natural antimicrobials with high potential in biomedicine. Pharmaceutics. 2021;14(1):76. doi:10.3390/pharmaceutics14010076.
   PubMed Web of Science ®Google Scholar
• Shin JM, Gwak JW, Kamarajan P, Fenno JC, Rickard AH, Kapila YL. Biomedical applications of nisin. J Appl Microbiol. 2016;120(6):1449–1465. doi:10.1111/jam.13033.
   PubMed Web of Science ®Google Scholar
• Bartoloni A, Mantella A, Goldstein BP, Dei R, Benedetti M, Sbaragli S, Paradisi F. In-vitro activity of nisin against clinical isolates of Clostridium difficile. J Chemother. 2004;16(2):119–121. doi:10.1179/joc.2004.16.2.119.
   PubMed Web of Science ®Google Scholar
• O’Reilly C, O’Connor PM, O’Sullivan Ó, Rea MC, Hill C, Ross RP. Impact of nisin on Clostridioides difficile and microbiota composition in a faecal fermentation model of the human colon. J Appl Microbiol. 2022b;132(2):1397–1408. doi:10.1111/jam.15250.
   PubMed Web of Science ®Google Scholar
• van Kraaij C, Breukink E, Noordermeer MA, Demel RA, Siezen RJ, Kuipers OP, de Kruijff B. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry. 1998;37(46):16033–16040. doi:10.1021/bi980931b.
   PubMed Web of Science ®Google Scholar
• Fooks LJ, Gibson GR. Mixed culture fermentation studies on the effects of synbiotics on the human intestinal pathogens Campylobacter jejuni and Escherichia coli. Anaerobe. 2003;9(5):231–242. doi:10.1016/S1075-9964(03)00043-X.
   PubMed Web of Science ®Google Scholar
• Blanco-Míguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, Manghi P, Dubois L, Huang KD, Thomas AM. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol. 2023;41(11):1633–1644. doi:10.1038/s41587-023-01688-w.
   PubMed Web of Science ®Google Scholar
• RStudio Team. RStudio: integrated development for R. RStudio; 2020.
   Google Scholar
• Wickham HG. 2016. 2: elegant graphics for data analysis. In: Data analysis. Springer International publishing; p. 189–201.
   Google Scholar
• Yadav MK, Tiwari SK. Methods for determination of antimicrobial activity of bacteriocins of lactic acid bacteria. Microbiology. 2023;92(6):745–765. doi:10.1134/S0026261723600520.
   Web of Science ®Google Scholar
• Mathur H, Rea MC, Cotter PD, Hill C, Ross RP. The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells. Gut Pathog. 2016;8(1):1–10. doi:10.1186/s13099-016-0102-8.
   PubMedGoogle Scholar
• Lay CL, Dridi L, Bergeron MG, Ouellette M, Fliss IL. Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. J Med Microbiol. 2016;65(2):169–175. doi:10.1099/jmm.0.000202.
   PubMedGoogle Scholar
• Wood K. Microbial ecology: complex bacterial communities reduce selection for antibiotic resistance. Curr Biol. 2019;29(21):R1143–R1145. doi:10.1016/j.cub.2019.09.017.
   PubMed Web of Science ®Google Scholar
• Mathur H, Mechoud MA, Matthews C, Lordan C, FitzGerald JA, Beresford T, Cotter PD. Methods to mitigate Escherichia coli blooms in human ex vivo colon model experiments using the high throughput micro-matrix bioreactor fermentation system. MethodsX. 2023;11:102393. doi:10.1016/j.mex.2023.102393.
   PubMed Web of Science ®Google Scholar
• O’Donnell MM, Rea MC, Shanahan F, Ross RP. The use of a mini-bioreactor fermentation system as a reproducible, high-throughput ex vivo batch model of the distal colon. Front Microbiol. 2018;9:391591. doi:10.3389/fmicb.2018.01844.
   Web of Science ®Google Scholar
• Long B, Gottlieb M. Oral fidaxomicin versus vancomycin for Clostridioides difficile infection. Acad Emerg Med. 2022;29(12):1506–1507. doi:10.1111/acem.14600.
   PubMed Web of Science ®Google Scholar
• Basolo A, Hohenadel M, Ang QY, Piaggi P, Heinitz S, Walter M, Walter P, Parrington S, Trinidad DD, von Schwartzenberg RJ. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nat Med. 2020;26(4):589–598. doi:10.1038/s41591-020-0801-z.
   PubMed Web of Science ®Google Scholar
• Kim E, Kim AH, Lee Y, Ji SC, Cho J, Yu K, Chung J. Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects. Clin Transl Sci. 2021;14(5):1955–1966. doi:10.1111/cts.13051.
   PubMed Web of Science ®Google Scholar
• Nazzal L, Soiefer L, Chang M, Tamizuddin F, Schatoff D, Cofer L, Aguero-Rosenfeld ME, Matalon A, Meijers B, Holzman R. Effect of vancomycin on the gut microbiome and plasma concentrations of gut-derived uremic solutes. Kidney Int Rep. 2021;6(8):2122–2133. doi:10.1016/j.ekir.2021.05.014.
   PubMed Web of Science ®Google Scholar
• Jarrad AM, Blaskovich MAT, Prasetyoputri A, Karoli T, Hansford KA, Cooper MA. Detection and investigation of eagle effect resistance to vancomycin in clostridium difficile with an ATP-bioluminescence assay. Front Microbiol. 2018;9:332066. doi:10.3389/fmicb.2018.01420.
   Web of Science ®Google Scholar
• Marchandin H, Anjou C, Poulen G, Freeman J, Wilcox M, Jean-Pierre H, Barbut F. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. J Antimicrob Chemother. 2023;78(8):1992–1999. doi:10.1093/jac/dkad194.
   PubMed Web of Science ®Google Scholar
• Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell EA. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. 2022;604(7906):541–545. doi:10.1038/s41586-022-04545-z.
   PubMed Web of Science ®Google Scholar
• Costa DVS, Pham NVS, Hays RA, Bolick DT, Goldbeck SM, Poulter MD, Hoang SC, Shin JH, Wu M, Warren CA. Influence of binary toxin gene detection and decreased susceptibility to antibiotics among Clostridioides difficile strains on disease severity: a single-center study. Antimicrob Agents Chemother. 2022;66(8):e00489–22. doi:10.1128/aac.00489-22.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26(6):305–312. doi:10.1155/2015/934594.
   PubMed Web of Science ®Google Scholar
• Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH. SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother. 2015;70(1):182–189. doi:10.1093/jac/dku324.
   PubMed Web of Science ®Google Scholar
• Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother. 2014;58(10):5714–5718. doi:10.1128/AAC.02903-14.
   PubMed Web of Science ®Google Scholar
• Collins DA, Riley TV. Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Lett Appl Microbiol. 2022;75(3):526–536. doi:10.1111/lam.13664.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872–4876. doi:10.1128/AAC.01136-13.
   PubMed Web of Science ®Google Scholar
• Bublitz A, Brauer M, Wagner S, Hofer W, Müsken M, Deschner F, Lesker TR, Neumann-Schaal M, Paul L-S, Nübel U. et al. The natural product chlorotonil a preserves colonization resistance and prevents relapsing Clostridioides difficile infection. Cell Host & Microbe. 2023;31(5):734–750.e8. doi:10.1016/j.chom.2023.04.003.
   PubMed Web of Science ®Google Scholar
• Gerth K, Steinmetz H, Höfle G, Jansen R. Chlorotonil A, a macrolide with a unique gem‐dichloro‐1, 3‐dione functionality from sorangium cellulosum, so ce1525. Angew Chem Int Ed. 2008;47(3):600–602. doi:10.1002/anie.200703993.
   PubMed Web of Science ®Google Scholar
• Jungmann K, Jansen R, Gerth K, Huch V, Krug D, Fenical W, Müller R. Two of a kind the biosynthetic pathways of chlorotonil and anthracimycin. ACS Chem Biol. 2015;10(11):2480–2490. doi:10.1021/acschembio.5b00523.
   PubMed Web of Science ®Google Scholar